Cytokinetics’ Myqorzo secured twin efficacy targets in a Phase 3 trial of non-obstructive hypertrophic cardiomyopathy (ACACIA), providing a counterpoint to Bristol Myers Squibb’s Camzyos efforts in the same therapeutic landscape. The company reported statistically significant improvement in both heart failure symptom burden and cardiovascular fitness. Myqorzo is already in early commercial launch for the more severe obstructive form of HCM, but the Phase 3 success could broaden eligibility if regulators clear the non-obstructive indication. Analyst forecasts cited by commentators suggest the addressable market could expand materially with an ACACIA-positive outcome. Separately, reporting notes the trial result differentiates Myqorzo from rival approaches by establishing efficacy in a closely watched, genetically driven subtype. For biotech and pharma decision-makers, the update is a reminder that HCM is an area where label expansion can quickly change revenue expectations if confirmatory data align.